Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) was the recipient of a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 33,053 shares, a drop of 59.6% from the September 30th total of 81,750 shares. Based on an average daily trading volume, of 679,428 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company’s shares are sold short.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on CHGCY shares. Nomura raised shares of Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. UBS Group lowered Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy”.
Get Our Latest Analysis on Chugai Pharmaceutical
Chugai Pharmaceutical Stock Performance
OTCMKTS:CHGCY traded up $0.68 during trading hours on Friday, hitting $21.82. The company’s stock had a trading volume of 125,618 shares, compared to its average volume of 261,850. The business’s 50-day moving average is $20.74 and its two-hundred day moving average is $24.55. Chugai Pharmaceutical has a 52-week low of $18.33 and a 52-week high of $34.84. The company has a market capitalization of $71.84 billion, a PE ratio of 22.73 and a beta of 0.60.
Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $0.27 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 35.63% and a return on equity of 24.91%. The company had revenue of $2.54 billion during the quarter, compared to analysts’ expectations of $2.29 billion. As a group, analysts predict that Chugai Pharmaceutical will post 1.00 EPS for the current fiscal year.
Chugai Pharmaceutical Company Profile
Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.
The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.
Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.
Further Reading
- Five stocks we like better than Chugai Pharmaceutical
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
